DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
-
- STATUS
- Recruiting
Summary
This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors.
Description
The purpose of this study is to evaluate the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 overall response rate (ORR) in subsets of patients with advanced rare cancers treated with ipilimumab plus nivolumab combination immunotherapy.
FAQ
Details
| Condition | Bronchioloalveolar Carcinoma,Adrenal Cortex Carcinoma,Adrenal Gland Pheochromocytoma,Acinar Cell Carcinoma |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX7674 |
| Last Modified on | 19 February 2024 |
Eligibility
How to participate?
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.